These molecular mechanisms indicated that SMN2 gene could be a goodtarget for SMA disease therapy, meaning the increase of fl–SMN protein level.Different compounds are tested in order to accomplish this aim. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.